Table 3 Baseline characteristics of the patients in the sharp and phase I/II trial
From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Characteristics | SHARP trial | Phase I/II trial | P value |
|---|---|---|---|
Age, years | 64.9 | 69.4 | 0.22 |
Male no (%) | 260 (87 %) | 80 (78.4 %) | 0.244 |
Underlying liver disease | 0.011 | ||
Hepatitis B | 56 (19 %) | 39 (38.2 %) | |
Hepatitis C | 87 (29) | 39 (38.2 %) | |
Alcohol related | 79 (26 %) | 25 (24.5 %) | |
Other | 28 (9 %) | 14 (13.7 %) | |
Unkown | 49 (16 %) | 7 (6.9) | |
ECOG performance status n (%) | 0.225 | ||
0 | 161 (54 %) | 85 (83.3) | |
1 | 114 (38 %) | ||
2 | 24 (8 %) | 11 (10.8 %) | |
BCLC stage | 0.208 | ||
B (intermediate) | 54 (18 %) | 35 (34.3 %) | |
C (advanced) | 244 (82 %) | 67 (65.7 %) | |
Child-Pugh class, no (%) | < 0.0001 | ||
A | 284 (95 %) | 102 (100 %) | |
B | 14 (5 %) | 0 % | |
Biochemical analysis | 0.25 | ||
Albumin (g/dl) | 3.9 | 4.0 | |
Total bilirubin (mg/dl) | 0.7 | 1.3 | |
Alpha-fetoprotein | 44.3 ng/ml | 163 nmol/L | |
Previous therapy | 0.079 | ||
Surgery | 57 (19 %) | 9 (8.8 %) | |
TACE | 86 (29 %) | 22 (21.6 %) | |
RFA | 17 (6 %) | 35 (34.3 %) | |
PEI | 28 (9 %) | 16 (15.7 %) | |
Extrahepatic spread (no,%) | 159 (53 %) | 12 (11.8 %) | < 0.0001 |
Vascular invasion (no,%) | 108 (36 %) | 20 (49 %) | < 0.0001 |